LOM initiates Watchlist coverage of Cynapsus

Loewen Ondaatje McCutcheon has initiated “Watchlist” coverage of Cynapsus Therapeutics (TSX-V:CTH), calling the company a “potential breakout story that investors should be looking at now.” “With a current market capitalization of only $7 million, we believe there are some potential near-to medium-term valuation inflections, and little downside risk,” writes analyst Maria Luckevich. “More importantly, management [...]

Conceptus receives FDA approval for upgraded label

Conceptus (NASDAQ:CPTS) says the FDA has approved labeling changes to the use of Hologic’s bipolar radio frequency NovaSure Impedance Controlled Endometrial Ablation System, following the placement of Conceptus’ Essure inserts and a successful Essure confirmation test. The expanded label change followed the company and the FDA reaching an agreement on a post-approval study protocol. The [...]

Registration opens for Rodman & Renshaw’s 14th Annual Healthcare Conference

Organizers of this year’s Rodman & Renshaw Annual Global Investment Conference have just announced that the popular event will be held on September 9-11, 2012 at The Waldorf=Astoria in New York.  Those interested in attending this upcoming conference can now register online here. Writers and editors from Biotuesdays.com will be there and we hope to meet as [...]

pSivida gets nod in European approval process of Iluvien

pSivida (NASDAQ:PSDV; ASX:PVA) has obtain a the positive outcome of the Decentralized Procedure (DCP) for the approval of Iluvien in Europe. The announcement follows the issuance of the Final Assessment Report to pSivida’s licensee, Alimera Sciences, from the Reference Member State (RMS), the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA), and [...]

NY approval of ColonSentry opens door for GeneNews

Last week’s approval by New York State of GeneNews’ (TSX:GEN) ColonSentry molecular diagnostic test to determine a person’s risk of having colorectal cancer opens the door to the entire U.S. market and other jurisdictions around the world for the simple blood test. “Our lead product has now been approved by the most stringent level of [...]

Isotechnika to present at BioPartnering NA 2012

Isotechnika Pharma (TSX:ISA) CEO Dr. Robert Foster will participate in a BioPartnering North America 2012 conference workshop entitled, “Need + Innovation = Opportunity,” this afternoon at the Vancouver Convention Center. “We are delighted to be given this opportunity to share with a global audience the continued progress of our voclosporin program,” Dr. Foster said in [...]

Cellceutix completes cGMP manufacturing of Kevetrin

Lyophilization Services of New England has completed cGMP manufacturing of Kevetrin, Cellceutix’s (OTCBB:CTIX) novel cancer compound for multi-drug resistant cancers, for an upcoming Phase 1 clinical trial. Vials of Kevetrin will now undergo quality control testing and stability studies, which are expected to take a little more than a month. That will be followed by [...]

Brainsway receives Frost & Sullivan 2012 innovation award

Brainsway (TASE:BRIN) has received the Frost & Sullivan 2012 Global New Product Innovation Award in neuro-psychiatric devices for its Deep TMS system. “Brainsway’s deep Transcranial Magnetic Stimulation (TMS) is the only innovative, noninvasive technique that can be used for treatment of depression and other neuro-psychiatric disorders without causing any significant side effects,” the Frost & [...]

TearLab to explore commercial partnership opportunities in Japan

TearLab (NASDAQ:TEAR; TSX:TLB) has entered into a consulting agreement with one of its directors, Dr. Adrienne Graves, who will oversee identifying and leading discussions with potential partners for the commercialization of the TearLab Osmolarity System in Japan. Dr. Graves has been a member of TearLab’s board since April 2005. She was CEO of Santen Inc., [...]

Brainsway posts positive blood-brain opening results

Final results of a clinical trial using Brainsway’s (TASE:BRIN) high-intensity Deep TMS treatment protocols have induced a “temporary but significant” opening of the blood-brain barrier in 10 of 12 patients with brain tumors, compared with a control group. The clinical trial confirms and extends findings of a previous animal study conducted at Ben-Gurion University. Blood-brain [...]

Next Page »